摘要
目的:评价蚓激酶治疗血管性痴呆(Vascular dementia,VD)的有效性及安全性。方法:65例VD患者以蚓激酶联合尼莫地平或尼莫地平单独使用进行12周的治疗,按简易精神状态量表(MMSE)、日常生活能力量表(ADL)进行治疗前后的疗效评定,并测定凝血功能了解其安全性。结果:蚓激酶联合尼莫地平使VD患者MMSE及ADL评分显著改善(21.8±1.8),(40.5±5.0),效果优于尼莫地平单独使用(P<0.01);治疗组PT、APTT延长,纤维蛋白原降低(12.41±1.87),(36.35±1.12),(3.64±0.70),与对照组相比有显著性差异(P<0.05),但无明显出血倾向。结论:蚓激酶联合尼莫地平能有效治疗VD,耐受性较好。
Objective： To assess the efficacy of lumbrokinase in treatment of VD. Methods：65 cases were dcvidcd into two groups：contol and lumbrokinase group,treated respectively with nimodipine or nimodipine plus lumbrokinase.At baseline and after 12 weeks of treatment MMSE and ADL tests were taken. Results： There were remarkable differences in MMSE, and ADL between the two groups （P〈0.01）and the scores of lumbrokinase group were （ 21.8 ±1.8 ）, （ 40.5± 5.0 ） .In lumbrokinase group,PT and APTF were prolonged and the concerntration of the serum fibrinogen decreased. Conclusion：Lumbrokinase is effective in treating VD.Lumbrokinase is safe and well-tolerated.
出处
《辽宁中医药大学学报》
CAS
2008年第11期5-7,共3页
Journal of Liaoning University of Traditional Chinese Medicine
